News

Neurotronics becomes a subsidiary of Nihon Kohden on December 31, 2008. Nihon Kohden is expected to strengthen its position as a leader in the neurology business with the

NicVAX is an investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX is designed to stimulate the immune system to produce antibodies

Zolpimist is NovaDel’s second product approved by the FDA that uses the company’s proprietary NovaMist oral spray technology. Zolpimist contains zolpidem tartrate, the same active ingredient as Ambien,

ViRexx has three proprietary technology platforms Chimigen vaccine platform, T-ACT platform and the AIT platform. The Chimigen platform is a versatile platform technology being used primarily to generate

The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women, and treatment and prevention of bone loss in patients

The FDA has accepted an investigational new drug application (IND) for ARQ 621, and the company plans to initiate a Phase I clinical trial with this compound in

Under the terms of the agreement, AstraZeneca is expected to pay Map Pharmaceuticals an upfront cash payment of $40m and an additional $35m upon the successful achievement of primary endpoint

The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant

Under the terms of the agreement, the license grants exclusive rights to Drais to develop and commercialize DTS-108 worldwide. In return, Diatos is expected to receive an upfront payment, development